Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU1LXS)

Drug Name
Trastuzumab emtansine Drug Info
Indication
Disease Entry ICD 11 Status REF
HER2-positive breast cancer 2C60-2C65 Phase 3 [1]
Breast cancer 2C60-2C65 Phase 2 [1]
Cross-matching ID
PubChem CID
166596981
TTD Drug ID
DMU1LXS
INTEDE Drug ID
DR1629

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
DOT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [7]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [8]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [9]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [10]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [11]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [12]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [13]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [14]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [8]
Verapamil DMA7PEW Angina pectoris BA40 Approved [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [16]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [17]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [18]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [19]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [20]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [21]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [22]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [23]
Verapamil DMA7PEW Angina pectoris BA40 Approved [24]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By NADPH-dependent carbonyl reductase 3 (CBR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [25]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [26]
Phenanthrene-9,10-dione DMG8KS9 Discovery agent N.A. Investigative [27]
1H-Indole-2,3-dione DMOZ91H Discovery agent N.A. Investigative [28]
Nitrobenzaldehyde DM4UHB5 N. A. N. A. Investigative [25]
ACMC-209cv7 DMQCSFB N. A. N. A. Investigative [25]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Aldo-keto reductase 1C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [29]
FENOFIBRIC ACID DMGO2MC Cardiovascular disease BA00-BE2Z Approved [30]
ANDROSTERONE DMITJAK N. A. N. A. Phase 3 [31]
4-oxo-nonenal DMPX1J9 Discovery agent N.A. Investigative [32]
Acenaphthenol DMT3QYZ N. A. N. A. Investigative [31]
Indan-1-ol DMMLQZJ N. A. N. A. Investigative [31]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Aldo-keto reductase 1C1 (AKR1C1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [33]
FENOFIBRIC ACID DMGO2MC Cardiovascular disease BA00-BE2Z Approved [30]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [34]
Dihydrotestosterone DM3S8XC Prostate hyperplasia GA90 Phase 4 [33]
BRN-3548355 DM4KXT0 N. A. N. A. Investigative [35]
Drug(s) Metabolized By Aldo-keto reductase 1C4 (AKR1C4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [34]
Norethindrone acetate DMDGCQP N. A. N. A. Approved [36]
BRN-3548355 DM4KXT0 N. A. N. A. Investigative [35]
Drug(s) Metabolized By Aldo-keto reductase 1C2 (AKR1C2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FENOFIBRIC ACID DMGO2MC Cardiovascular disease BA00-BE2Z Approved [30]
BRN-3548355 DM4KXT0 N. A. N. A. Investigative [35]
Drug(s) Affected By Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [37]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [38]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [39]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [40]
Gefitinib DM15F0X Colon adenocarcinoma Approved [41]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [42]
Selenium DM25CGV N. A. N. A. Approved [43]
Methotrexate DM2TEOL Anterior urethra cancer Approved [44]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [47]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [48]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [49]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [50]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [51]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [52]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [53]
Gefitinib DM15F0X Colon adenocarcinoma Approved [54]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [55]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [57]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [48]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [58]
Paclitaxel DMLB81S Breast carcinoma Approved [59]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [60]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [47]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [37]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [61]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [50]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [51]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [2]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [3]
Aldo-keto reductase 1C3 (AKR1C3) DEGQTXO AK1C3_HUMAN Substrate [4]
Aldo-keto reductase 1C1 (AKR1C1) DE7P2FB AK1C1_HUMAN Substrate [4]
Aldo-keto reductase 1C2 (AKR1C2) DEOY5ZM AK1C2_HUMAN Substrate [4]
Aldo-keto reductase 1C4 (AKR1C4) DEAJN47 AK1C4_HUMAN Substrate [4]
NADPH-dependent carbonyl reductase 3 (CBR3) DEIVKZ8 CBR3_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Gene/Protein Processing [5]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Gene/Protein Processing [5]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Protein Interaction/Cellular Processes [6]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
3 Trastuzumab emtansine. An inadequately assessed combination of two cytotoxic drugs. Prescrire Int. 2014 Dec;23(155):289.
4 The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
5 CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
6 Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013 Dec 1;273(2):298-313. doi: 10.1016/j.taap.2013.09.003. Epub 2013 Sep 12.
7 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
8 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
9 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
10 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
11 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
13 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
15 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
17 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
18 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
19 Drug Interactions Flockhart Table
20 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
21 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
22 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
23 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
24 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
25 Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
26 Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
27 Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
28 Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis. Chem Biol Interact. 2009 Mar 16;178(1-3):234-41.
29 Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
30 In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
31 Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
32 Instability of C154Y variant of aldo-keto reductase 1C3. Chem Biol Interact. 2017 Oct 1;276:194-202.
33 Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
34 Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
35 Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
36 Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
37 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
38 Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
39 Down-regulation of HER-2 expression in human breast cancer cell HBC-4 and ZR75-1 by nitrogen-mustard-N-oxide. Kobe J Med Sci. 2007;53(4):135-42.
40 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
41 Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005 Oct 15;11(20):7480-9. doi: 10.1158/1078-0432.CCR-05-0328.
42 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
43 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
44 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
45 Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
46 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
47 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
48 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
49 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
50 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
51 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
52 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
53 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
54 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
55 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
56 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
57 Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
58 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
59 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
60 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
61 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.